aRCC: 1L Treatment Options and Patient Management

 

PrecisCa
Avatar

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After Multiple Lines of Systemic Therapy

By PrecisCa FEATURING Matthew Rettig, Susan Slovin, Tyler Fraum, Jason Abel, Pretesh Patel
By PrecisCa FEATURING Matthew Rettig, Susan Slovin, Tyler Fraum, Jason Abel, Pretesh Patel
197 views
December 28, 2022
1 Comment
Login to view comments. Click here to Login
aRCC: 1L Treatment Options and Patient Management
12:14
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

Feat. S. Tykodi
08:40
Thomas Hutson

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

16:00
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

Feat. M. Dean
09:23
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

Feat. R. McKay
16:34
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

Feat. N. Haas
06:04
ASCO 2022 Conference Coverage

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA…

Feat. L. Albiges
47:32
Moffitt Cancer Center

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…

Feat. J. Gao
13:28
Total Health

2022 ASCO Renal Cell Carcinoma Updates

Feat. M. Bupathi
12:53
O'Neal Comprehensive Cancer Center at UAB

Dual Immunotherapy in RCC

Feat. A. Basu
20:47
ecancer

ESMO 2022 on the Latest in mRCC

Feat. J. Puente, B. Escudier, V. Grünwald, S. Oudard
21:09
Mário Fontes-Sousa

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

20:23
Aly-Khan A. Lalani

Choosing Wisely: 1L Combination Treatment for Advanced RCC

06:50
ecancer

ESMO 2022 Updates in Renal Cancer

Feat. T. Choueiri
19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

10:55
Yale Cancer Center

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Feat. D. Braun
14:14
PrecisCa

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

Feat. M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel